EAACI Congress 2025
BackOAS13 - Diagnosis and management of Eosinophilic Esophagitis
Sunday 15 Jun, 09:00 AM -
10:30 AM Glasgow, United Kingdom
Carron 1
Oral Abstract Sessions
09:00
Dupilumab Treatment Reduces IgE Levels in Patients Aged 2 to 17 Years With Atopic Dermatitis, Asthma, and Eosinophilic Esophagitis
09:12
Disrupted mucosal vascular barrier in adult patients with eosinophilic esophagitis
09:24
Dupilumab Is Efficacious in Children Aged 1–11 Years Weighing ≥15 kg With Eosinophilic Esophagitis Irrespective of Individual Atopic Comorbidities: 16-Week Results From the Phase 3 EoE KIDS Study
09:36
Dupilumab decreases the number of days with dysphagia in adult and adolescent patients with eosinophilic esophagitis: post hoc analysis of LIBERTY EoE TREET study
09:48
Cross-Sectional Real-World Survey of Adult Patients with Eosinophilic Oesophagitis: Symptom Burden and Adaptive Behaviours
10:00
Outcomes of food reintroduction and identification of food triggers in paediatric eosinophilic gastritis
10:12
Reference values of Eosinophilic Derived-Neurotoxin in blood of adults: reasons to use EDTA plasma
